Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/sctm.18-0008 http://scihub22266oqcxt.onion/10.1002/sctm.18-0008 C6052613!6052613!29752869     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Stem+Cells+Transl+Med 2018 ; 7 (7): 521-9 Nephropedia Template TP {{tp|p=29752869|t=2018. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study |pdf=|usr=}}{{29752869}} gab.com Text Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study JO: Stem Cells Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=29752869 #FOAvip Stroke is a major cause of death and long?term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic stroke is tissue plasminogen activator; however, relatively few patients are eligible for this therapy. We hypothesized that intravenous (IV) infusion of banked unrelated allogeneic umbilical cord blood (UCB) would improve functional outcomes in patients with ischemic stroke. To investigate this, we conducted a phase I open?label trial to assess the safety and feasibility of a single IV infusion of non?human leukocyte antigen (HLA) matched, ABO matched, unrelated allogeneic UCB into adult stroke patients. Ten participants with acute middle cerebral artery ischemic stroke were enrolled. UCB units were matched for blood group antigens and race but not HLA, and infused 3?9 days post?stroke. The adverse event (AE) profile over a 12 month postinfusion period indicated that the treatment was well?tolerated in these stroke patients, with no serious AEs directly related to the study product. Study participants were also assessed using neurological and functional evaluations, including the modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS). At 3 months post?treatment, all participants had improved by at least one grade in mRS (mean 2.8?±?0.9) and by at least 4 points in NIHSS (mean 5.9?±?1.4), relative to baseline. Together, these data suggest that a single i.v. dose of allogeneic non?HLA matched human UCB cells is safe in adults with ischemic stroke, and support the conduct of a randomized, placebo?controlled phase 2 study. stemcellstranslationalmedicine2018;7:521?529 Twit Text FOAVip Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study ????Stem Cells Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=29752869 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29752869 #FOAvip English Wikipedia <ref>{{Cite pmid|29752869}}</ref> Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study #MMPMID29752869 Laskowitz DT; Bennett ER; Durham RJ; Volpi JJ; Wiese JR; Frankel M; Shpall E; Wilson JM; Troy J; Kurtzberg J Stem Cells Transl Med 2018[Jul]; 7 (7): 521-9 PMID29752869show ga Stroke is a major cause of death and long?term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic stroke is tissue plasminogen activator; however, relatively few patients are eligible for this therapy. We hypothesized that intravenous (IV) infusion of banked unrelated allogeneic umbilical cord blood (UCB) would improve functional outcomes in patients with ischemic stroke. To investigate this, we conducted a phase I open?label trial to assess the safety and feasibility of a single IV infusion of non?human leukocyte antigen (HLA) matched, ABO matched, unrelated allogeneic UCB into adult stroke patients. Ten participants with acute middle cerebral artery ischemic stroke were enrolled. UCB units were matched for blood group antigens and race but not HLA, and infused 3?9 days post?stroke. The adverse event (AE) profile over a 12 month postinfusion period indicated that the treatment was well?tolerated in these stroke patients, with no serious AEs directly related to the study product. Study participants were also assessed using neurological and functional evaluations, including the modified Rankin Score (mRS) and National Institute of Health Stroke Scale (NIHSS). At 3 months post?treatment, all participants had improved by at least one grade in mRS (mean 2.8?±?0.9) and by at least 4 points in NIHSS (mean 5.9?±?1.4), relative to baseline. Together, these data suggest that a single i.v. dose of allogeneic non?HLA matched human UCB cells is safe in adults with ischemic stroke, and support the conduct of a randomized, placebo?controlled phase 2 study. stemcellstranslationalmedicine2018;7:521?529 äAllogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stro(epmc).pdf DeepDyve Pubget Overpricing